Kaushik has been in the drug discovery space for 15+ years focused on metabolic disease, specifically type II diabetes, obesity, and NAFLD/NASH. He has identified a human development antisense compound for NASH that has completed Phase II clinical trials. His research and development expertise encompasses metabolic disease, In Vivo and In Vitro Pharmacology, and translational medicine. In my current role as Head of Translational Sciences, I oversee the scientific cross-functionality and validity of the computational models as they apply to the drug development space. He has extensive experience working with small molecules and antisense compound modalities.
Kaushik has been in the drug discovery space for 15+ years focused on metabolic disease, specifically type II diabetes, obesity, and NAFLD/NASH. He has identified a human development antisense compound for NASH that has completed Phase II clinical trials. His research and development expertise encompasses metabolic disease, In Vivo and In Vitro Pharmacology, and translational medicine. In my current role as Head of Translational Sciences, I oversee the scientific cross-functionality and validity of the computational models as they apply to the drug development space. He has extensive experience working with small molecules and antisense compound modalities.